A STRUCTURED MODELING APPROACH OF PEPTIC ULCERS AND H. PYLORI INFECTION

  • Do, Tae-Sug (DEPARTMENT OF MATHEMATICS EDUCATION, KWANDONG UNIVERSITY) ;
  • Ledder, Glenn (DEPARTMENT OF MATHEMATICS, UNIVERSITY OF NEBRASKA-LINCOLN) ;
  • Lee, Young-S. (DEPARTMENT OF MATHEMATICS AND COMPUTER SCIENCE, N. MANCHESTER)
  • Received : 2008.12.16
  • Accepted : 2009.02.26
  • Published : 2009.03.25

Abstract

Current therapies against ulcers caused by H. pylori infection consist of antibiotics, an acid reducer, and some clinical trials underway to develop a H. pylori vaccine. We develop a structured model with age-dependent mortality of peptic ulcers and H. pylori infection. Our main goal is to analyze our structured model mathematically and to compare it to our previously unstructured model to examine the disease transmission dynamics in terms of annual prevalence and annual incidence of the disease.

References

  1. Centers for Disease Control and Prevention www.cdc.gov/ulcer/md.htm
  2. National Digestive Disease Information Clearinghouse http://digestive.niddk.nih.gov/ddiseases/pubs/hpylori
  3. S. Becker, R. Smalligan, J, H. Kleanthous, T. Tibbitts, T. Manath and K. Hyamset, Risk of H. pylori infection among long-term residents in developing countries, Am. J. Trop. Med. Hyg., 60 (1999)
  4. L.G. Robinson, F.L. Black, F.K. Lee, A.O. Sousa, M. Owens, D. Danielson, A.J. Nahmias, B.D. Gold, Helicobacter pylori prevalence among indigenous peoples of South America, J. Infect Dis, 186 (2002)
  5. Veterans and Agent Orange: Update 2004 (2005), Board on Health Promotion and Disease Prevention, The National Academic Press
  6. E. Kuipers, Helicobacter pylori and the risk and management of associated diseases: gastritis, ulcer disease, atrophic gastritis and gastric cancer. Aliment Pharmacol Ther, 11 (1997)
  7. K. Knigge, The role of H. pylori in gastrointestinal disease, Postgraduate Medicine, 110 (2001)
  8. Proceedings of the fourth Global Vaccine Research Forum, Department of immunization, Vaccines and Biological World Health Organization, Geneva, Switzerland
  9. P. Rugglero, S. Peppoloni, D. Berti, R. Pappuoli, G. Del Gludice, Expert Opinion on Investigational Drugs, 11 (2002)
  10. D. Burmann, P.R. Jungblut, T.F. Meyer, Helicobacter pylori vaccine development based on combined subproteome analysis, Proteomics 4 (2004)
  11. F. Hardin, R. Wright, Helicobacter pylori: Review and Update, Hospital Physicians, May (2002)
  12. AHT Jeremy, Y. Du, M.F. Dixon, P.A. Robinson, J.E. Crabtree, Protection against Helicobacter pylori infection in the Mongolian gerbil after prophylactic vaccination, Microbes and Infection, 8 (2006)
  13. Tae S. Do, Glenn Ledder, Young Lee, The Dynamics of Peptic Ulcers and H. Pylori with Vaccination, International Journal of Pure and Applied Mathematics, 43 (2008)
  14. M. Susser, Z. Stein, Civilization and peptic ulcer, Lancet, 20 (1962)
  15. M. Rupnow, R. Shachter, D. Owens, J. Parsonnet, A Dynamic Tranmission Model for Prediction Trends in Helicobacter pylori and Associated Diseases in the United States, Emerging Infections Diseases, 6 (2000)
  16. M. Rupnow, R. Shachter, D. Owens, J. Parsonnet, Quantifying the population impact of a prophylactic Helicobacter pylori vaccine, Vaccine 20 (2002)
  17. P. Ven den Driessche and J. Watmough, Reproduction numbers and sub-threshold Endemic Equilia for Compartmental models of disease transmission, 180 (2002)
  18. National Center for Health Statistics http://www.cdc.gov/nchs/fastats/lifexpec.htm